Please login to the form below

Not currently logged in
Email:
Password:

OncoVex

This page shows the latest OncoVex news and features for those working in and with pharma, biotech and healthcare.

AZ signs yet another cancer immunotherapy deal

AZ signs yet another cancer immunotherapy deal

The most advanced is Amgen's OncoVex (talimogene laherparepvec), which in 2013 became the first oncolytic virus to show efficacy in a phase III trial involving people with the skin cancer

Latest news

  • Amgen says viral melanoma therapy clears phase III trial Amgen says viral melanoma therapy clears phase III trial

    OncoVex demonstrates durable response in skin cancer patients. A novel therapy for skin cancer which makes use of the cell-killing activity of a virus has shown efficacy in a phase ... The melanoma immunotherapeutic - talimogene laherparepvec (also known

  • Disease focus: Melanoma

    nilotinib. In development. Vaccines. OncoVEX GM-CSF. In development. Vaccines. MAGE-A3 ASCI.

  • Amgen to buy BioVex

    BioVex's portfolio includes OncoVex (GM-CSF) – an investigational vaccine to treat melanoma and head and neck cancer. ... Philip Astley-Sparke, CEO, BioVex, also praised the agreement: "Amgen is ideally positioned to leverage the potential of OncoVEX

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics